Functional microsphere as well as preparation method and application thereof

Functional microspheres formed by reverse suspension polymerization and coaxial microfluidics have solved the problems of poor encapsulation and rapid drug release in existing microspheres for tumor treatment. They have achieved thermally stimulated self-shrinkage and self-adhesion, enabling strong drug encapsulation and targeted sustained-release therapy.

CN119015477APending Publication Date: 2024-11-26SUZHOU INST OF NANO TECH & NANO BIONICS CHINESE ACEDEMY OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411130130.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing microspheres have drawbacks in tumor treatment, such as poor encapsulation, insufficient elasticity, and rapid drug release, making it difficult to achieve dense embolization and targeted sustained-release therapy.

Method used

Microsphere shell structures are formed using reverse suspension polymerization and coaxial microfluidics technology, encapsulating drugs in the core of the microspheres. The microspheres are then solidified through photopolymerization. These functional microspheres possess thermally stimulating self-shrinkage and self-adhesion properties, enabling strong drug encapsulation and targeted sustained release.

Benefits of technology

It achieves long-term targeted sustained-release therapy of drugs. The microspheres do not become blocked after passing through the microcatheter, have good biocompatibility and mechanical strength, and can achieve strong blockage and slow drug release at the tissue site.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015477A_ABST
    Figure CN119015477A_ABST
Patent Text Reader

Abstract

The invention provides a functional microsphere and a preparation method and application thereof, the preparation method comprises the following steps: (1) adding methacrylic anhydride into a polymer solution, and reacting to obtain a polymer derivative; (2) adding a monomer, a cross-linking agent and a photoinitiator into the polymer derivative solution to obtain a precursor solution, transferring the precursor solution into a first injector, and sealing and keeping out of light; (3) putting the functional molecule solution into a second injector; mounting a first injector and a second injector on a first injection pump and a second injection pump respectively, and then mounting and connecting the first injector and the second injector with an outer needle and an inner needle of a coaxial dispensing needle respectively; and (4) dropwise adding the mixed liquid drops into a reaction medium, stirring, curing and forming to obtain the functional microspheres. The functional microsphere has an obvious thermal stimulation self-constriction behavior, so that the drug wrapping property is stronger, and drug targeted slow-release treatment is realized; and meanwhile, the adhesive force is generated with the tissue part, so that the high plugging property of embolism treatment is further realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomaterials and relates to a functional microsphere and a preparation method and application thereof. Background Art

[0002] For cancer patients, surgical resection is currently the most effective clinical treatment method, but for patients who are elderly, have multiple underlying diseases, or have poor cardiopulmonary function and cannot tolerate surgery, interventional embolization or chemotherapy is the preferred option. Primary liver cancer is the fourth most common malignant tumor and the second leading cause of death from tumors in my country, of which hepatocellular carcinoma accounts for as high as 75% to 85%. In August 2023, the "Chinese Clinical Practice Guidelines for Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma" (hereinafter referred to as the new version of the guidelines) were updated and comprehensively summarized the latest clinical practices and high-level evidence-based medicine evidence of TACE, and systematically explained the important position and value of TACE in the treatment of hepatocellular carcinoma. The new hot spots in the new version of the guidelines point out that new embolic agents and embolization methods (temperature-sensitive hydrogels) provide direction for the development of TACE.

[0003] At present, many clinical centers have tried to use different embolic agents, including gelatin sponge particles, PVA particles, iodized oil, NBCA embolic agents, etc. The most important type of these embolic agents is drug-loaded microspheres, namely drug-eluting microspheres. Since drug-loaded microsphere preparations have long-lasting sustained release or targeting effects, they can greatly improve the convenience and compliance of patients' medication, including but not limited to the advantages of drug concentration in the tumor, slow release, low drug concentration in peripheral non-target organs, and small systemic byproducts. Therefore, it has shown its advantages in clinical practice and is a highly effective dosage form. Therefore, it is widely used in primary liver tumors and metastatic tumors. In addition, it is also used in other solid tumors, such as bladder cancer, lung cancer, kidney cancer, bone and soft tissue tumors, etc., and has shown good safety and effectiveness.

[0004] However, existing microspheres have disadvantages such as poor coating, insufficient elasticity, and rapid drug release.

[0005] Therefore, in the art, it is desirable to develop a functional microsphere whose thermally stimulated contractility and self-adhesiveness can achieve the potential of dense embolization and targeted sustained-release therapy. Summary of the invention

[0006] In view of the shortcomings of the prior art, the purpose of the present invention is to provide a functional microsphere and a preparation method and application thereof. The present invention forms a microsphere shell structure by reverse suspension polymerization and coaxial microfluidics technology and constructs the drug in the core of the microsphere; finally, the functional microsphere is solidified and formed by a photopolymerization process. The functional microsphere has obvious thermal stimulation self-contraction behavior, that is, the automatic contraction phenomenon after reaching the equilibrium of swelling-thermal stimulation automatic contraction, which makes the drug and / or developer more encapsulated, and at the same time adheres to the application tissue site, and has strong embolic properties and the potential for targeted sustained-release therapy.

[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0008] In a first aspect, the present invention provides a method for preparing functional microspheres, the preparation method comprising the following steps:

[0009] (1) dissolving a polymer material in a solvent to form a polymer solution, then adding methacrylic anhydride, reacting, and post-treating to obtain a polymer derivative;

[0010] (2) dissolving the polymer derivative obtained in step (1) in a solvent to obtain a polymer derivative solution, adding a monomer, a cross-linking agent and a photoinitiator thereto, dissolving in the dark to obtain a precursor solution, transferring the precursor solution into a first syringe, and sealing the syringe to avoid light;

[0011] (3) dissolving the functional molecule in a solvent to form a functional molecule solution, placing the functional molecule solution in a second syringe, and sealing it to avoid light; setting the operating parameters of the two syringe pumps, and installing the first syringe and the second syringe on the first syringe pump and the second syringe pump, respectively, and then removing the sealing heads of the two syringes and installing and connecting them to the outer needle and the inner needle of the coaxial dispensing needle respectively;

[0012] (4) preparing a reaction medium, and then placing it a certain distance below the coaxial dispensing needle in step (3) so that the needle is suspended above the reaction medium, turning on the operation switches of the two injection pumps in step (3), and dripping the mixed liquid droplets into the reaction medium at a uniform speed. After the dripping is completed, stirring is continued for a certain period of time and then stopped, solidified and formed, and post-processed to obtain the functional microspheres.

[0013] The functional microspheres obtained by the preparation method of the present invention include microspheres and functional molecules loaded in the microspheres.

[0014] The functional microspheres formed by the present invention through reverse suspension polymerization and coaxial microfluidic technology include a coating layer and the drug is encapsulated in situ in the inner core of the microsphere; the coating layer realizes rapid cross-linking and curing through a photopolymerization strategy, effectively protecting the drug in the core area; not only that, the functional microspheres also have obvious temperature sensitivity (thermal stimulation self-contraction behavior) so that the drug encapsulation is stronger, thereby achieving the advantage of long-term targeted sustained-release therapy. In addition, the hydrogel properties of the functional microspheres have good elasticity, so that it can pass through the microcatheter smoothly, and quickly return to its original state after passing through the microcatheter without blocking the microcatheter. The functional microspheres also have the ability to form a synergistic system by combining natural materials and synthetic materials, which not only exerts good biocompatibility and mechanical strength, but also has key properties such as low immunogenicity and tolerance to protein adsorption.

[0015] In addition, since the surface of the functional microspheres has a variety of functional groups (amino, carboxyl, vinyl) and can be modified on various carriers (such as scaffolds, biofilms, etc.), they also have great application prospects in reproductive tissue regeneration, bone repair, skin defect repair, etc. In particular, the surface of the microspheres has succinimidyl ester groups, which can react with the amino groups of the tissue proteins at the application site to form a nucleophilic substitution reaction (covalent bond), that is, to produce adhesion with the tissue site.

[0016] Preferably, the polymer material in step (1) is a natural polymer material.

[0017] Preferably, the natural polymer material includes any one or a combination of at least two of collagen, human recombinant collagen, chitosan, silk fibroin, chondroitin sulfate, alginate, hyaluronic acid, and trilysine, or may be a modified state of the above materials (such as cross-linking or chemical modification), preferably collagen.

[0018] Preferably, the solvent in step (1) comprises any one of water, acetic acid, and dimethyl sulfoxide, or a combination of at least two thereof.

[0019] Preferably, in step (1), based on 100 mL of the solvent, the amount of the polymer material is 0.1 to 1 g, for example, 0.1 g, 0.2 g, 0.3 g, 0.4 g, 0.5 g, 0.6 g, 0.7 g, 0.8 g, 0.9 g, 1 g, etc.

[0020] Preferably, in step (1), based on 100 mL of the solvent, the amount of methacrylic anhydride used is 0.1 to 10 mL, for example, 0.1 mL, 0.3 mL, 0.5 mL, 0.8 mL, 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, 10 mL, etc.

[0021] Preferably, the reaction in step (1) is carried out in the dark.

[0022] Preferably, the reaction in step (1) is carried out under magnetic stirring.

[0023] Preferably, the speed of the magnetic stirring is 100-300 r / min, for example, 100 r / min, 150 r / min, 200 r / min, 250 r / min, 300 r / min, etc.

[0024] Preferably, the post-treatment in step (1) includes dialysis purification and freeze-drying.

[0025] Preferably, the molecular weight cut-off of the dialysis bag used for dialysis purification is 3500-14000Da.

[0026] Preferably, the solvent in step (2) comprises any one of water, acetic acid, and dimethyl sulfoxide, or a combination of at least two thereof.

[0027] Preferably, the monomer in step (2) includes any one or a combination of at least two of acrylate-N-succinimidyl ester (AA-NHS), four-arm polyethylene glycol-N-hydroxysuccinimide-glutarate (4-Arm-PEG-SG), N-isopropylacrylamide (NIPAM), hydroxyethyl methacrylate (HEMA), dimethylaminoethyl methacrylate (DMAEMA), diacetone acrylamide (DMOBAA), ethylene glycol methacrylate (EGMA), β-acryloxypropionic acid (CEA), and N,N'-diethylacrylamide (DEAA); preferably acrylate-N-succinimidyl ester and N-isopropylacrylamide.

[0028] Preferably, the cross-linking agent in step (2) comprises methylene bisacrylamide.

[0029] Preferably, the photoinitiator in step (2) includes any one of phenyl (2,4,6-trimethylbenzoyl) phosphate lithium salt, α-ketoglutaric acid, 1-hydroxycyclohexyl phenyl ketone, and 2-hydroxy-2-methyl-1-phenylpropanone, or a combination of at least two thereof.

[0030] Preferably, in step (2), based on 100 mL of the solvent, the amount of the polymer derivative is 1 to 5 g, for example, 1 g, 1.5 g, 2 g, 2.5 g, 3 g, 3.5 g, 4 g, 4.5 g, 5 g, etc.

[0031] Preferably, in step (2), based on the amount of the solvent as 100 mL, the amount of the monomer is 0.1 to 5 g, for example, 0.1 g, 0.2 g, 0.3 g, 0.4 g, 0.5 g, 0.6 g, 0.7 g, 0.8 g, 0.9 g, 1 g, 1.5 g, 2 g, 2.5 g, 3 g, 3.5 g, 4 g, 4.5 g, 5 g, etc., and the amount of the cross-linking agent is 0.01 to 0.5 g, for example, 0.01 g, 0.03 g, 0.05 g, 0.08 g, 0.1 g, 0.2 g, 0.3 g, 0.4 g, 0.5 g, etc.

[0032] Preferably, in step (2), based on the amount of monomer used being 100 mg, the amount of initiator used is 1 to 15 mg, for example, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg, 10 mg, 10.5 mg, 11 mg, 11.5 mg, 12 mg, 12.5 mg, 13 mg, 13.5 mg, 14 mg, 14.5 mg, 15 mg, etc.

[0033] Preferably, the functional molecules in step (3) include drugs and / or active factors.

[0034] Preferably, the drug includes any one of antibacterial agents, antibiotic drugs, anti-inflammatory drugs, and immunomodulatory drugs, or a combination of at least two of them.

[0035] Preferably, the drug comprises any one of curcumin, idarubicin, cisplatin, ligustrazine, icariin, epirubicin, pharmacine, and crystal violet, or a combination of at least two of them.

[0036] Preferably, the drug can also use other auxiliary components to achieve functions including microspheres being able to image themselves, breaking the pH value of the tumor microenvironment, having hemostatic ability, etc., and such components are not particularly limited and can be selected from: inorganic components, for example, one or more combinations of graphene oxide, metal oxide magnetic nanoparticles, bioactive glass, etc. Moreover, collagen functional microspheres can specifically bind to bioactive factors to give the microspheres bioactive functions because the component type I collagen has a collagen-specific binding region (CBD). Such bioactive factors are not particularly limited and can be selected from: basic fibroblast growth factor (bFGF), vascular endothelial growth factor, platelet-derived growth factor, angiogenin, etc.

[0037] Preferably, the active factors include any one of basic fibroblast growth factor (bFGF), matrix metalloproteinase 9 (MMP9), brain-derived neurotrophic factor (BDNF), neurotrophin III (NT-3), or a combination of at least two of them.

[0038] Preferably, the solvent in step (3) includes any one of water, saline, and dimethyl sulfoxide, or a combination of at least two of them.

[0039] Preferably, in step (3), based on 100 mL of the solvent, the amount of the functional molecule is 1 to 5 g, for example, 1 g, 1.5 g, 2 g, 2.5 g, 3 g, 3.5 g, 4 g, 4.5 g, 5 g, etc.

[0040] Preferably, the operating parameters of the injection pump in step (3) are that the injection speed of the first injection pump is 1 to 20 mL / h, for example, 1 mL / h, 3 mL / h, 5 mL / h, 8 mL / h, 10 mL / h, 12 mL / h, 14 mL / h, 16 mL / h, 18 mL / h, 20 mL / h, etc., and the injection speed of the second injection pump is 0.01 to 5 mL / h, for example, 0.01 mL / h, 0.03 mL / h, 0.05 mL / h, 0.08 mL / h, 0.1 mL / h, 0.3 mL / h, 0.5 mL / h, 0.8 mL / h, 1 mL / h, 2 mL / h, 3 mL / h, 4 mL / h, 5 mL / h, etc.

[0041] Preferably, the coaxial dispensing needle in step (3) includes any one of coaxial dispensing two needles, coaxial dispensing three needles, and coaxial dispensing four needles, or a combination of at least two of them. Taking the coaxial dispensing three needles as an example, it includes (a) an outer needle and two parallel inner needles, (b) an outer needle plus an intermediate needle and an inner needle, preferably two coaxial dispensing needles.

[0042] Preferably, the two coaxial dispensing needles include an inner needle and an outer needle with flush outlets, an inner needle protruding 0.1 to 0.5 mm (for example, 0.1 mm, 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, etc.), and an inner needle retracting 0.1 to 0.3 mm (for example, 0.1 mm, 0.2 mm, 0.3 mm, etc.), preferably, the inner needle protrudes 0.2 mm.

[0043] Preferably, the inner needle specification of the two coaxial dispensing needles is 21-32G, such as 21G, 23G, 25G, 28G, 30G, 32G, etc., and the outer needle specification is 10-25G, such as 10G, 13G, 15G, 18G, 20G, 23G, 25G, etc., preferably 28G / 18G or 30G / 21G.

[0044] Because biological tissue damage is often accompanied by the loss of nerves, blood vessels and muscles, it is necessary to take different measures for the regeneration of different functional tissues. Based on the functional microspheres we constructed, the inner layer of the microspheres is loaded with drugs or other components with the longest controlled release cycle as the second gradient; the outer layer of the microspheres is loaded with drugs or other necessary components with a slower controlled release cycle as the first gradient; gradient release and targeted treatment are performed. Of course, under the premise of safety, an optional preparation process is beneficial to the expected goal of improving clinical treatment effects: loading two or more drugs in the inner needle process of the coaxial two-needle dispensing needle or performing a coaxial three-needle dispensing needle preparation process.

[0045] Preferably, the reaction medium in step (4) is a mixture of dimethyl silicone oil and Span 80, and the volume ratio of dimethyl silicone oil to Span 80 is 100:0.1-5, where 0.1-5 can be, for example, 0.1, 0.3, 0.5, 0.8, 1, 2, 3, 4, 5, etc.

[0046] Preferably, in step (4), the distance below the coaxial dispensing needle is 1 to 10 mm, for example, 1 mm, 2 mm, 3 mm, 4 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, 10 mm, etc.; and the suspension above the reaction medium is in a vertical direction or a horizontal direction.

[0047] Preferably, the dripping rate of the droplets in step (4) is 10 to 60 drops / minute, for example, 10 drops / minute, 15 drops / minute, 20 drops / minute, 25 drops / minute, 30 drops / minute, 35 drops / minute, 40 drops / minute, 45 drops / minute, 50 drops / minute, 55 drops / minute, 60 drops / minute, etc.

[0048] Preferably, the stirring speed in step (4) is 50 to 200 r / min, for example, 50 r / min, 80 r / min, 100 r / min, 120 r / min, 140 r / min, 160 r / min, 180 r / min, 200 r / min, etc., and the stirring method is a magnetic stirrer or a stirring paddle.

[0049] Preferably, the stirring time in step (4) is 5 to 20 min, for example, 5 min, 10 min, 15 min, 20 min, etc.

[0050] Preferably, the curing method in step (4) is photoinitiation or thermal initiation, preferably ultraviolet light initiation.

[0051] Preferably, the ultraviolet light wavelength is 330-450nm, for example 330nm, 350nm, 380nm, 400nm, 430nm, 450nm, etc., and the ultraviolet light irradiation time is 1-5min, for example 1min, 2min, 3min, 4min, 5min, etc., to achieve rapid curing and molding and avoid diffusion of functional molecules inside the core.

[0052] Preferably, the post-treatment in step (4) comprises centrifuging to remove the upper layer of the reaction medium, washing with an organic solvent to remove the remaining reaction medium, and finally washing with pure water and freeze-drying.

[0053] Preferably, the centrifugal speed is 500-1000 r / min, such as 500 r / min, 600 r / min, 800 r / min, 1000 r / min, etc., and the centrifugal time is 3-8 min, such as 3 min, 4 min, 5 min, 8 min, etc.

[0054] Preferably, the organic solvent is selected from any one of anhydrous ether, anhydrous ethanol, toluene, or a combination of at least two thereof, preferably anhydrous ethanol.

[0055] In a second aspect, the present invention provides a functional microsphere, wherein the functional microsphere is prepared by the preparation method described in the first aspect.

[0056] Preferably, the functional microspheres are of intelligent response type, including temperature response type, and preferably have thermal stimulation self-contraction behavior in the temperature response type.

[0057] Preferably, the shrinkage deformation of the functional microspheres is 1-50%, for example, 1%, 3%, 5%, 8%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, etc.

[0058] Preferably, the functional microspheres have self-adhesive properties and are easy to form a bonding force of nucleophilic substitution reaction with the amino groups of proteins in the tissue site, thereby adhering to the tissue, and the lap-shear strength thereof is 1 to 1000 KPa, for example 1 KPa, 5 KPa, 10 KPa, 30 KPa, 50 KPa, 80 KPa, 100 KPa, 300 KPa, 500 KPa, 800 KPa, 1000 KPa, etc.

[0059] Preferably, the functional microspheres have a mechanical strength of 0.1 to 10 MPa, such as 0.1 MPa, 0.3 MPa, 0.5 MPa, 0.8 MPa, 1 MPa, 3 MPa, 5 MPa, 8 MPa, 10 MPa, etc., a deformation range of 10 to 200%, such as 10%, 30%, 50%, 80%, 100%, 120%, 140%, 160%, 180%, 200%, etc., an elastic modulus of 0.01 to 1 MPa, such as 0.01 MPa, 0.03 MPa, 0.05 MPa, 0.08 MPa, 0.1 MPa, 0.3 MPa, 0.5 MPa, 0.8 MPa, 1 MPa, etc., and can remain in their original shape after being pressurized through a catheter.

[0060] Preferably, the surface structure of the functional microspheres is a smooth spherical structure, which is not easy to clog the catheter.

[0061] Preferably, the degradation period of the functional microspheres is 7 to 365 days, for example, 7 days, 10 days, 15 days, 20 days, 1 month, 3 months, 6 months, 10 months, 12 months, etc., preferably 1 to 6 months.

[0062] Preferably, the functional microspheres are hydrogel structures with a swelling rate of 50 to 500% w / w, such as 50% w / w, 100% w / w, 200% w / w, 300% w / w, 400% w / w, 500% w / w, etc.

[0063] Preferably, the diameter of the functional microspheres is 1 μm to 50 mm, for example, 1 μm, 10 μm, 50 μm, 100 μm, 500 μm, 800 μm, 1 mm, 5 mm, 10 mm, 20 mm, 30 mm, 40 mm, 50 mm, etc., preferably 100 to 1000 μm; the drugs are concentratedly loaded in the center of the microspheres to convert the original crystalline drugs into amorphous (amorphous) forms, which can improve their poor water solubility and low bioavailability caused by poor membrane permeability, and improve and maintain the drug concentration for a long time.

[0064] In a third aspect, the present invention provides a use of the functional microspheres as described in the first aspect in embolic therapy drugs.

[0065] Compared with the prior art, the present invention has the following beneficial effects:

[0066] (1) By adjusting the process parameters, customized functional microspheres with different particle sizes (two or more) can be prepared, and different drugs or functional factors can be loaded respectively, so that small-size functional microspheres can embolize the ends and large-size functional microspheres can embolize the branches, thereby achieving dense embolism.

[0067] (2) The functional microspheres can be completely cross-linked in vitro to avoid the heterogeneity of bulk hydrogels and achieve uniform mechanical properties and a large specific surface area. In addition, by selecting the monomers, the surface of the functional microspheres can have succinimide (NHS) ester groups, which can undergo a nucleophilic substitution reaction with the amino group of the tissue protein at the application site to form a bonding force (covalent bond), that is, to generate adhesion with the tissue site, further helping to achieve strong occlusion of embolic therapy.

[0068] (3) Two or more drug-loaded microspheres can realize a two-drug combination chemotherapy regimen. Since the functional microspheres have the characteristic of automatic contraction under thermal stimulation, when used for in vivo treatment, they have a stronger ability to encapsulate drugs, so the drug release process is particularly slow. In addition, the synthetic polymer components in the microspheres prolong the degradation cycle, so it is significantly better than the traditional drug infusion + drug-loaded microsphere regimen, especially for patients with time-dependent chemotherapy drugs.

[0069] (4) The self-adhesion property and thermal stimulation self-contraction property of the functional microspheres work synergistically to achieve targeted sustained-release therapy of drugs at the tissue site of administration, making them truly intelligent responsive drug-loaded microspheres. BRIEF DESCRIPTION OF THE DRAWINGS

[0070] Figure 1 These are actual pictures of hydrogel collagen microspheres of different sizes provided in Examples 1, 2, 3, and 4 of the present invention.

[0071] Figure 2 This is the nuclear magnetic resonance hydrogen spectrum diagram that proves the successful synthesis of methacryloylated collagen in Example 1 of the present invention.

[0072] Figure 3 A is a scanning electron microscope image of the collagen microspheres in Example 1 of the present invention.

[0073] Figure 3 B is the EDS spectrum result of the collagen microspheres provided in Example 1 of the present invention.

[0074] Figure 4 This is a size distribution diagram of the collagen microspheres provided in Example 1 of the present invention.

[0075] Figure 5 It is a graph showing the in vitro pigskin lap-shear strength performance test results of the microspheres provided in Example 1 of the present invention and Comparative Example 1.

[0076] Figure 6 This is an image of the temperature responsiveness performance test of the collagen microspheres provided in Example 1 of the present invention: automatic contraction upon thermal stimulation.

[0077] Figure 7 This is the appearance of the collagen microspheres provided in Example 1 of the present invention after 3 weeks of in vitro degradation ( Figure 7 (a) Figure 7 (b)) and mechanical strength test results (where Figure 7 (c) is the mechanical strength test result before degradation. Figure 7 (d) is the mechanical strength test result after 3 weeks of degradation).

[0078] Figure 8 This is a microscopic morphology picture of the collagen microspheres provided in Example 1 of the present invention after degradation for 3 months in vitro, wherein: Figure 8 (b) Yes Figure 8 Magnified image of the red area in (a).

[0079] Fig. 9 It is the in vitro sustained release comparison curve (9B) and the standard curve (9A) of the collagen microspheres loaded with curcumin provided in Example 1 and Comparative Example 3 of the present invention.

[0080] Fig.10 This is a laser confocal scanning fluorescence microscope image of the collagen microspheres loaded with curcumin provided in Example 1 of the present invention.

[0081] Fig.11 This is the XRD spectrum of the curcumin-loaded collagen microspheres provided in Example 1 of the present invention.

[0082] Fig.12 This is the CCK-8 detection of the proliferation of human umbilical vein endothelial cells in the collagen microsphere extract provided in Example 1 of the present invention.

[0083] Fig.13 It is the in vitro magnetic resonance (MRI) T1 and T2 weighted imaging of the collagen microspheres and imaging microspheres provided in Example 1 of the present invention.

[0084] Fig.14 This is a physical picture of hyaluronic acid functional microspheres loaded with crystal violet provided in Example 5 of the present invention.

[0085] Fig.15 These are the SEM image (15a) and the microscope image (15b) of the coaxial microspheres with missing core structure provided in Comparative Example 2 of the present invention. DETAILED DESCRIPTION

[0086] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0087] Data Analysis:

[0088] Origin software was used for data statistics. Data were expressed as mean ± standard deviation. Multiple groups of data (≥3 groups) with normal distribution and constant variance were tested for significance level using ANOVA; two groups of data were tested for significance level using Tukey Test. *P < 0.05 indicated a significant difference, and **P < 0.01 indicated an extremely significant difference.

[0089] Example 1

[0090] In this embodiment, a drug-loaded collagen microsphere is provided, and the preparation method comprises the following steps:

[0091] (1) Weigh 1g collagen (type I collagen, molecular weight of about 300kDa) and place it in a mixed solution of 200mL dimethyl sulfoxide and water (the volume ratio of dimethyl sulfoxide to water is 20:80), stir magnetically at room temperature at a stirring speed of 100r / min, stir for 6h to obtain a collagen solution, and slowly add 2mL of methacrylic anhydride to it. Continue to react with magnetic stirring for 24h at room temperature in the dark, dialyze in pure water with a dialysis bag with a molecular weight cutoff of 3500Da for one week, change the solution once a day, and then freeze-dry to obtain methacryloyl collagen (COL-MA). Seal and store at low temperature in the dark for later use.

[0092] (2) Weigh 200 mg of methacryloyl collagen and dissolve it in 5 mL of 0.5% acetic acid aqueous solution. Ultrasonic dissolution is complete and presents a flowing state (<35°C) to prepare COL-MA solution. Add 50 mg of N-isopropylacrylamide, 50 mg of acrylic acid-N-succinimidyl ester, 15 mg of methylenebisacrylamide and 7.5 mg of phenyl (2,4,6-trimethylbenzoyl) lithium phosphate, dissolve in the dark, and remove bubbles by centrifugation (2000 r / min, 5 min) during the dissolution and stirring process. Then obtain the photocurable mixed precursor solution, transfer it to the first syringe (2 mL), and seal it to avoid light.

[0093] (3) Dissolve 20 mg of curcumin in 1 mL of dimethyl sulfoxide and dissolve in a dark ultrasonic manner to obtain a curcumin solution, which is placed in a second syringe (2 mL) and sealed to avoid light. Turn on the syringe pump power switch, set the operating parameters of the two syringe pumps (the speed of the first syringe pump is 2 mL / h, and the speed of the second syringe pump is 0.05 mL / h), and then install the syringes in steps (2) and (3) on the syringe pumps in sequence, and finally remove the two syringe sealing heads and install them with the outer needle and inner needle of the coaxial dispensing needle (28G / 18G) respectively.

[0094] (4) Add 50mL of dimethyl silicone oil as the reaction medium to a 100mL beaker, and add 100μL of span80, and stir magnetically at room temperature at a speed of 80r / min for 15min. Then place it under the coaxial dispensing needle in step (3) so that the needle is suspended 2mm above the reaction medium. At the same time, turn on the operation switches of the two injection pumps in step (3) to start working, and drop the mixed liquid into the reaction medium at a uniform speed. After the addition is completed, continue stirring for 5min and then stop stirring. Turn on ultraviolet light irradiation for 5min. After the end, transfer it to a centrifuge tube and centrifuge at 500r / min for 5min to remove the upper silicone oil. Then wash it with ethanol 3 times to wash away the remaining silicone oil, and then wash it with pure water 3 times to remove ethanol to obtain hydrogel collagen functional microspheres ( Figure 1 ), the hydrogel-state functional microspheres can also be freeze-dried to obtain dry functional microspheres, which can then be sealed and stored at low temperature.

[0095] The actual pictures of hydrogel collagen microspheres of different sizes provided in this embodiment and the following embodiments 2, 3 and 4 are as follows: Figure 1 As shown, from Figure 1 It can be seen that the collagen microspheres are round and have good mechanical strength and elasticity (reference Figure 7 ), which can reduce the friction between collagen microspheres and catheters and improve injection efficiency. Therefore, collagen microspheres have a suitable mechanical property foundation.

[0096] The intermediates or microspheres provided in the preparation process of this embodiment were tested as follows:

[0097] (1) H NMR spectroscopy ( 1 H NMR) test

[0098] Weigh the same mass of collagen and methacryloyl collagen, place them in NMR tubes, add 450 μL of heavy water and 50 μL of deuterated acetic acid to the NMR tubes, vortex and ultrasonicate to completely dissolve them, place the NMR tubes in a NMR instrument for detection, and obtain the relevant samples. 1 H NMR. Figure 2 The results show that new characteristic peaks appear at 5.5ppm and 5.9ppm, which belong to the chemical shift of the target functional group (vinyl group); and there is a sharp peak at 2.5ppm belonging to the methyl group in the methacrylic group. 1 The H NMR spectrum showed that methacrylic groups were successfully introduced into the collagen molecular chain, thereby endowing it with free radical polymerization (photocuring and thermal curing) capabilities.

[0099] (2) Scanning electron microscope (SEM) observation of morphology, size and structure

[0100] The microspheres were sprayed with gold in a dry state, observed and photographed under a scanning electron microscope. The surface morphology was observed, and three fields of view were taken to calculate the diameter range of the microspheres. Figure 3 A Results show that the overall morphology of the collagen microspheres is relatively uniform from the surface morphology of the microspheres; Figure 3 B Energy spectrum analysis results show that the main elements of the microspheres are C, N, and O, while the trace element Si may come from the residual dimethyl silicone oil; the element P comes from the photoinitiator phenyl (2,4,6-trimethylbenzoyl) lithium phosphate; the element S belongs to dimethyl sulfoxide, but the content of the three elements is less than 1%. Figure 4 The results showed that the size distribution of collagen microspheres was gradient, mainly concentrated in 200-800μm, and the widest distribution range was 500-600μm. The results of scanning electron microscopy showed that collagen microspheres had a controllable size gradient and effective size distribution.

[0101] (3) Lap-shear strength test

[0102] The lap-shear strength test refers to YY / T 0729.1-2009. Select two pieces of pigskin with a size of 3cm*2.5cm, then place the test sample (1±0.1cm*2±0.1cm*5±1mm) flatly on one end of the pigskin, and quickly bond the two ends of the pigskin in opposite directions (the bonding surface is the effective area). Apply a force of 1N to the bonding area at room temperature for 1h, and stretch the specimen at a tensile speed of 5mm / min until the two pieces of pigskin break. Record the force-displacement data, draw a graph to analyze the force-displacement curve, and record the maximum shear force (F max ) Result calculation: Shear strength (MPa) = F max (N) / Force bearing area (mm 2 The in vitro pigskin lap-shear strength performance test results of the microspheres provided in Example 1 and Comparative Example 1 below are shown in FIG. Figure 5 shown.

[0103] (4) Temperature responsiveness test

[0104] In the experiment of repeated cycles in 25℃ and 37℃ water phase, the changes of microsphere swelling equilibrium-thermal stimulus automatic contraction (temperature responsiveness) equilibrium were observed within 2 minutes. Figure 6 It can be seen that a short-term thermal stimulation can achieve a significant change in the degree of thermal shrinkage that is higher than the degree of swelling of the hydrogel microspheres in water, resulting in a shrinkage phenomenon in which the collagen microspheres as a whole show a rounding trend. This lays a theoretical foundation for the subsequent study of collagen microspheres loaded with drugs for in vivo (37°C): the automatic shrinkage behavior after the swelling balance-thermal stimulation automatic shrinkage balance makes the drug packaging stronger and thus achieves a sustained release effect.

[0105] (5) In vitro degradation performance

[0106] The collagen microspheres in Example 1 were placed in a PBS buffer at 37°C and pH 7.4 for 3 weeks, and their appearance and mechanical strength were observed. Figure 7 It can be seen that the collagen microspheres in hydrogel state still have certain mechanical strength and adhesion properties after 3 weeks of degradation. After adhering to tweezers and clamped with tweezers, the structure remains intact. The microspheres also have good elasticity, that is, they can return to their original state after the external force (tweezers) is removed. The collagen microspheres were then tested for long-term in vitro degradation performance to simulate the dynamic process in in vivo tissue fluid: placed in a 37°C PBS solution, shaken at 80r / min, with a degradation cycle of 3 months, and characterized by scanning electron microscopy. Figure 8 It can be seen that after 3 months of in vitro degradation, the overall structure of the collagen microspheres still remains intact, and the microscopic surface morphology is comparable to that of the undegraded microspheres (reference Figure 3 ) The difference is not big, but the local magnified image shows the subtle changes in the surface morphology of the microspheres - some surfaces become rough. This shows that the collagen microspheres have mechanical support strength for at least 3 months.

[0107] (6) Drug sustained release performance of drug-loaded collagen microspheres

[0108] Accurately weigh 2.5 mg of curcumin into a 50 mL volumetric flask and dilute to volume with 50% (v / v) ethanol solution to prepare a stock solution. Then, different volumes (1 μL, 2 μL, 5 μL, 10 μL, 20 μL, 50 μL, 100 μL, 200 μL, 400 μL, 600 μL, 1 mL, 2 mL) of the stock solution were respectively pipetted into 5 mL of PBS solution to accurately prepare a series of standard solutions with concentrations of 0.01 ug / mL, 0.02 ug / mL, 0.05 ug / mL, 0.1 ug / mL, 0.2 ug / mL, 0.5 ug / mL, 0.98 ug / mL, 1.92 ug / mL, 3.7 ug / mL, 5.36 ug / mL, 8.33 ug / mL, and 14.29 ug / mL. The wavelength of the absorption peak was determined to be 423 nm by spectral scanning. The absorbance of the standard solution was measured at this wavelength. The absorbance (A) was linearly regressed against the curcumin concentration (C) to obtain the regression equation and draw a standard curve (see Fig. 9 A).

[0109] The collagen microspheres loaded with curcumin were placed in a sustained-release medium: PBS (pH 7.4) solution containing ethanol (0.5%), and an in vitro drug release experiment was conducted for 3 months. 0.5 mL of samples were taken at 0, 4 h, 1 d, 3 d, 6 d, 10 d, 15 d, 40 d, and 90 d, and the same amount of sustained-release medium was added at the same temperature. The sample was blanked with 0.5% ethanol in PBS solution. The absorbance was measured at 423 nm, and the concentration was calculated according to the regression equation to calculate the cumulative drug release (see Fig. 9 B). Fig. 9 B The results show that the microspheres of Example 1 continuously release the drug curcumin in a 3-month in vitro sustained-release environment, wherein the release rate in the first 6 days is very slow, and the release amount accounts for only one-fifth of the total amount in the release period, and the release amount in the last 75 days accounts for nearly half of the total amount in the entire release period, indicating that the release process is slow. Therefore, the functional collagen microspheres have the ability to control the release of drugs.

[0110] (7) Fluorescence performance detection of drug-loaded collagen microspheres

[0111] The curcumin-loaded collagen microspheres were observed by laser confocal scanning fluorescence microscopy and scanned images were taken. Fig.10 The results showed that the overall morphology of the collagen microspheres in the hydrogel state was spherical and uniform in size. Curcumin's own fluorescence was green after laser irradiation, and the strong green fluorescence was distributed inside the microspheres, indicating that curcumin was mainly concentrated inside the collagen microspheres. Therefore, the collagen microspheres have the function of loading and encapsulating fluorescent substances, indicating that they have the ability of fluorescent labeling.

[0112] (8) X-ray diffraction (XRD) detection of the dispersion form of curcumin in collagen microspheres

[0113] XRD test information is: instrument model: Rigaku Miniflex 600, target: Cu-Kα radiation, wavelength: 1.5406A, tube voltage: 40KV, tube current: 40mA, step length: 0.02°, scanning speed: 1° / min, scanning range: 5~90°. Fig.11 As shown, the X-ray diffraction pattern of curcumin powder has a strong diffraction peak between 5 and 40°, confirming its crystalline characteristics, while the XRD pattern of curcumin loaded by microspheres has no sharp diffraction peaks, showing a lack of crystallinity, indicating that curcumin is well encapsulated in the functional microspheres, and the curcumin molecules exist in an amorphous form in the functional microspheres, and the amorphous form of curcumin can improve its poor water solubility and low bioavailability caused by poor membrane permeability. Curcumin delivered in the form of functional microspheres has the effect of increasing and maintaining drug concentration for a long time, which also provides an application method for other drugs with low bioavailability.

[0114] (9) Cytotoxicity assay of collagen microspheres

[0115] 1) Cell recovery: Shake and thaw the cryotube containing 1 mL of human umbilical vein endothelial cell (HUVEC, hereinafter referred to as cells) suspension quickly in a 37°C water bath, add 5 mL of culture medium and mix well. Centrifuge at 1000 r / min for 5 min, discard the supernatant, add 5 mL of complete culture medium and blow evenly. Then add all the cell suspension to the culture flask and culture overnight (or add the cell suspension to a 6 cm culture dish) and culture overnight. Change the medium and check the cell density the next day.

[0116] 2) Cell subculture: If the cell density reaches 80%-90%, subculture can be performed.

[0117] 3) Preparation of microsphere extract: The collagen microspheres were first soaked in anhydrous ethanol for 2 h for sterilization. After removing the anhydrous ethanol, they were washed with PBS buffer for 3 times, each time for 10 min. The microspheres were then placed in complete culture medium of human umbilical vein endothelial cells and extracted at 4°C for 3 weeks.

[0118] 4) Cell inoculation and culture: 2000 cells were inoculated in each well of a 96-well plate, with 3 wells in each group. 100 μL of culture medium was added to each well. After culturing for 24 h, the original culture medium was removed. The control group used a simple culture medium, while the experimental group used a microsphere extract and a 1-fold diluted extract. The culture was continued for 1 d and 4 d, respectively, and the medium was changed every 2 days.

[0119] 5) Color development: After the corresponding culture time is over, add 10 μL of CCK-8 directly into the cell culture medium. Mix thoroughly to ensure that the color in each well is consistent, but no bubbles are generated, and continue to culture for 2 hours.

[0120] 6) Detection: The absorbance (OD) value was read using an ELISA reader, and dual wavelengths were used for determination, with the detection wavelength being 450 nm and the reference wavelength being 650 nm.

[0121] from Fig.12 It can be seen that during the 4-day culture, especially with the extension of culture time, both the collagen microsphere extract solution group and the 1-fold diluted group showed good cell compatibility. Although the collagen microsphere extract solution group showed obvious differences after the first day of culture, this was related to the long-term extraction (3 weeks) of our collagen microspheres. Considering the long-term accumulation of toxins, the differences in cell culture on the first day were acceptable.

[0122] (10) Preparation of imaging collagen microspheres

[0123] Superparamagnetic iron oxide (Fe3O4) is a commonly used contrast agent in magnetic resonance imaging (MRI), and the U.S. Food and Drug Administration (FDA) has approved dextran-coated iron oxide nanoparticles (Feridex) as a T2 contrast agent for clinical use. According to their mechanism, contrast agents are divided into T1 contrast agents and T2 contrast agents. T1 contrast agents can make the marked area brighter, while T2 contrast agents make the marked area darker.

[0124] 1) Weigh 200 mg of methacryloyl collagen and dissolve it in 5 mL of 0.5% acetic acid solution. Ultrasonic dissolution is complete and presents a flowing state (<35°C) to prepare COL-MA solution. Add 10 mg / mL N-isopropylacrylamide, 3 mg / mL methylenebisacrylamide and 3% (w / w) phenyl (2,4,6-trimethylbenzoyl) phosphate lithium salt to it, dissolve in the dark, and remove bubbles by centrifugation (2000r / min, 5min) if bubbles are generated during the dissolution and stirring process. Then obtain the light-cured mixed precursor solution, transfer it to the first syringe (2 mL), and seal it to avoid light.

[0125] 2) Transfer 500 μL of Fe3O4 aqueous solution (4 mg / mL) to the second syringe (1 mL), seal and protect from light. Turn on the syringe pump power switch, set the operating parameters of the two syringe pumps respectively (the speed of the first syringe pump is 6 mL / h, and the speed of the second syringe pump is 1 mL / h), and then install the syringes in steps 1) and 2) on the syringe pumps in sequence, and finally remove the two syringe sealing heads and install them with the outer needle and inner needle of the coaxial dispensing needle (28G / 18G) respectively.

[0126] 3) Add 50mL of dimethyl silicone oil as the reaction medium to a 100mL beaker, and add 100μL of span80, stir magnetically at room temperature, the stirring speed is 100r / min, and the stirring time is 10min. Then place it under the coaxial dispensing needle in step 2) so that the needle is suspended 2mm above the reaction medium. At the same time, turn on the operation switches of the two injection pumps in step 2) to start working, and the mixed liquid droplets are dripped into the reaction medium at a uniform speed. After the addition is completed, continue stirring for 2min and then stop stirring. Turn on ultraviolet light irradiation for 5min. After the end, transfer to a centrifuge tube, centrifuge at 2000r / min, 3min, remove the upper silicone oil, and then wash with ethanol 3 times to wash away the remaining silicone oil, and then wash with pure water 3 times to remove ethanol to obtain hydrogel-developed collagen functional microspheres.

[0127] T1-weighted and T2-weighted images of collagen microspheres and contrast microspheres were taken using a small animal magnetic resonance imaging system (Bruker, 7.0T MRI Biospoin GmbH, Pharma Scan7016). Fig.13 It can be seen that the collagen microspheres (without the addition of contrast agent) are grayish white in magnetic resonance imaging (T1 or T2), making the marked area brighter, while the contrast microspheres make the marked area darker, which is consistent with the reports in the literature. This shows that the contrast-functional collagen microspheres have visualization and thus achieve positioning effects, laying the foundation for MRI to clearly show the embolic effect of contrast microspheres.

[0128] Example 2

[0129] The only difference between this embodiment and embodiment 1 is that the specifications of the coaxial dispensing needles (two) in step (3) are different: 25G / 16G, and the operating parameters of the injection pumps are adjusted to: the speed of the first injection pump is 5mL / h, and the speed of the second injection pump is 0.5mL / h. Microspheres of a certain size are prepared.

[0130] Example 3

[0131] The only difference between this embodiment and embodiment 1 is that the specifications of the coaxial dispensing (two) needles are different: 25G / 16G, and the operating parameters of the injection pump are adjusted to: the speed of the first injection pump is 8mL / h, and the speed of the second injection pump is 1mL / h, so as to prepare microspheres of a certain size.

[0132] Example 4

[0133] The only difference between this embodiment and embodiment 1 is that the specifications of the coaxial dispensing (two) needles are different: 24G / 14G, and the operating parameters of the injection pumps are adjusted to: the speed of the first injection pump is 10mL / h, and the speed of the second injection pump is 1.2mL / h, and microspheres of a certain size are prepared.

[0134] Example 5

[0135] In this embodiment, a drug-loaded hyaluronic acid microsphere is provided, and the preparation method comprises the following steps:

[0136] (1) Weigh 1 g of hyaluronic acid and place it in 200 mL of pure water. Stir magnetically at room temperature at a stirring speed of 100 r / min for 3 h to obtain a hyaluronic acid solution, to which 3 mL of methacrylic anhydride is slowly added. Continue to react with magnetic stirring for 24 h at room temperature in the dark, dialyze in pure water using a dialysis bag with a molecular weight cutoff of 3500 Da for one week, change the solution once a day, and then freeze-dry to obtain methacryloyl hyaluronic acid (HA-MA). Seal and store at low temperature in the dark for later use.

[0137] (2) Weigh 200 mg of HA-MA and dissolve it in 4 mL of pure water. Ultrasonic dissolution is complete and the solution is in a flowing state (<35°C) to prepare a HA-MA solution. Add 40 mg of N-isopropylacrylamide, 10 mg of methylenebisacrylamide and 6 mg of phenyl (2,4,6-trimethylbenzoyl) lithium phosphate to it and dissolve it in the dark. If bubbles are generated during the dissolution and stirring process, they can be removed by centrifugation (1000 r / min, 5 min). Then obtain the photocurable mixed precursor solution, transfer it to the first syringe (2 mL), and seal it to avoid light.

[0138] (3) Dissolve 10 mg of crystal violet in 1 mL of pure water and dissolve it in a dark ultrasonic manner to obtain a crystal violet solution, which is placed in a second syringe (2 mL) and sealed to avoid light. Turn on the syringe pump power switch, set the operating parameters of the two syringe pumps respectively (the speed of the first syringe pump is 3 mL / h, and the speed of the second syringe pump is 0.5 mL / h), and then install the syringes in steps (2) and (3) on the syringe pumps in sequence. Finally, remove the two syringe sealing heads and install them on the outer needle and inner needle of the coaxial dispensing needle (31G / 21G) respectively.

[0139] (4) Add 50mL of dimethyl silicone oil as the reaction medium to a 100mL beaker, and add 100μL of span80, and stir magnetically at room temperature at a speed of 80r / min for 15min. Then place it under the coaxial dispensing needle in step (3) so that the needle is suspended 3mm above the reaction medium. At the same time, turn on the operation switches of the two injection pumps in step (3) to start working, and drop the mixed liquid into the reaction medium at a uniform speed. After the addition is completed, continue stirring for 5min and then stop stirring. Turn on ultraviolet light irradiation for 5min. After the end, transfer it to a centrifuge tube and centrifuge at 500r / min for 5min to remove the upper silicone oil. Then wash it with ethanol 3 times to wash away the remaining silicone oil, and then wash it with pure water 3 times to remove ethanol to obtain hydrogel hyaluronic acid functional microspheres ( Fig.14 ), the hydrogel-state functional microspheres can also be freeze-dried to obtain dry functional microspheres, which can then be sealed and stored at low temperature.

[0140] Comparative Example 1

[0141] The only difference between this comparative example and Example 1 is that the monomer acrylic acid-N-succinimidyl ester in step (2) is removed, and the microspheres are prepared according to the same steps and parameters. In order to characterize its mechanical properties, the hydrogel blocks (1cm*2cm*5mm) of Example 1 and Comparative Example 1 were prepared by using a mold, and the in vitro pig skin adhesion performance test was carried out. The results showed that the lap-shear strength of Comparative Example 1 was significantly lower than that of Example 1 ( Figure 5 ), which proves that the sample in Example 1 has self-adhesive properties and can form adhesion with the applied tissue site to achieve a certain blocking effect.

[0142] Comparative Example 2

[0143] The only difference between this comparative example and Example 1 is that the curcumin in the second syringe in step (3) is removed and replaced by air. Turn on the power switch of the syringe pump, set the operating parameters of the two syringe pumps respectively (the speed of the first syringe pump is 2mL / h, and the speed of the second syringe pump is 0.02mL / h), and then install the syringes on the syringe pumps in order, and finally remove the two syringe sealing heads and connect them to the outer needle and inner needle of the coaxial dispensing needle (28G / 18G) to prepare microspheres. The microspheres in Comparative Example 2 and the microspheres in Example 1 were subjected to structural characterization experiments. The results show that the microspheres in Comparative Example 2 collapsed in the dry state compared with those in Example 1, resulting in obvious grooves and wrinkles on the appearance of the microspheres ( Fig.15 a), this is due to the lack of internal core structure of the microspheres in Comparative Example 1 ( Fig.15 b)-The interior is bright and transparent under the microscope.

[0144] Comparative Example 3

[0145] The only difference between this comparative example and Example 1 is that the coaxial dispensing needle (two) is replaced with a single-channel dispensing needle, and the same concentration and type of monomers, crosslinking agents, initiators and fluorescent drug curcumin are physically mixed, and microspheres are prepared using a single syringe and injection pump. The microspheres in comparative example 3 and the microspheres in Example 1 were subjected to in vitro drug release experiments. The results show that the in vitro drug release rate of the microspheres in comparative example 3 is significantly faster than that in Example 1 ( Fig. 9 ), which proves that the microspheres in Example 1 achieve the effect of long-term controlled drug release by constructing the drug in the inner core.

[0146] In summary, the present invention forms a microsphere shell structure by reverse suspension polymerization and coaxial microfluidics technology and constructs the drug in the microsphere core; finally, the functional microsphere is solidified and formed by photopolymerization process. The functional microsphere has obvious thermal stimulation self-contraction behavior, that is, the automatic contraction phenomenon after reaching the swelling equilibrium-thermal stimulation automatic contraction equilibrium, which makes the drug and / or developer more encapsulated, and at the same time adheres to the application tissue site, and has strong embolism and targeted sustained release therapy potential.

[0147] The applicant declares that the present invention uses the above-mentioned embodiments to illustrate the functional microspheres and the preparation method and application thereof, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of the raw materials selected by the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A method for preparing functional microspheres, It is characterized in that The preparation method comprises the following steps: (1) dissolving a polymer material in a solvent to form a polymer solution, then adding methacrylic anhydride, reacting, and post-treating to obtain a polymer derivative; (2) dissolving the polymer derivative obtained in step (1) in a solvent to obtain a polymer derivative solution, adding a monomer, a cross-linking agent and a photoinitiator thereto to obtain a precursor solution, transferring the precursor solution into a first syringe and sealing it to avoid light; (3) dissolving the functional molecule in a solvent to form a functional molecule solution, placing the functional molecule solution in a second syringe, and sealing it to avoid light; setting the operating parameters of the two syringe pumps, and installing the first syringe and the second syringe on the first syringe pump and the second syringe pump, respectively, and then removing the sealing heads of the two syringes and installing and connecting them to the outer needle and the inner needle of the coaxial dispensing needle respectively; (4) preparing a reaction medium, and then placing it a certain distance below the coaxial dispensing needle in step (3) so that the needle is suspended above the reaction medium, turning on the operation switches of the two injection pumps in step (3), and dripping the mixed liquid into the reaction medium. After the dripping is completed, stirring, curing and forming, and post-processing are performed to obtain the functional microspheres.

2. The preparation method according to claim 1, It is characterized in that The polymer material in step (1) is a natural polymer material; Preferably, the natural polymer material includes any one or a combination of at least two of collagen, human recombinant collagen, chitosan, silk fibroin, chondroitin sulfate, alginate, hyaluronic acid, and trilysine, preferably collagen; Preferably, the solvent in step (1) comprises any one of water, acetic acid, and dimethyl sulfoxide, or a combination of at least two thereof; Preferably, in step (1), the amount of the polymer material is 0.1 to 1 g based on 100 mL of the solvent; Preferably, in step (1), based on 100 mL of the solvent, the amount of methacrylic anhydride used is 0.1 to 10 mL.

3. The preparation method according to claim 1 or 2, It is characterized in that The reaction in step (1) is carried out under light protection; Preferably, the reaction in step (1) is carried out under stirring; Preferably, the post-treatment in step (1) includes dialysis purification and freeze-drying.

4. The preparation method according to any one of claims 1 to 3, It is characterized in that The solvent in step (2) includes any one of water, acetic acid, and dimethyl sulfoxide, or a combination of at least two thereof; Preferably, the monomer in step (2) comprises any one or a combination of at least two of acrylic acid-N-succinimidyl ester, four-arm polyethylene glycol-N-hydroxysuccinimide-glutarate, N-isopropylacrylamide, hydroxyethyl methacrylate, dimethylaminoethyl methacrylate, diacetone acrylamide, ethylene glycol methacrylate, β-acryloxypropionic acid, and N,N'-diethylacrylamide; preferably acrylic acid-N-succinimidyl ester and N-isopropylacrylamide; Preferably, the cross-linking agent in step (2) comprises methylene bisacrylamide; Preferably, the photoinitiator in step (2) includes any one or a combination of at least two of phenyl (2,4,6-trimethylbenzoyl) phosphate lithium salt, α-ketoglutaric acid, 1-hydroxycyclohexyl phenyl ketone, and 2-hydroxy-2-methyl-1-phenylpropanone; Preferably, in step (2), based on 100 mL of solvent, the amount of the polymer derivative is 1 to 5 g; Preferably, in step (2), based on 100 mL of the solvent, the amount of the monomer is 0.1 to 5 g, and the amount of the cross-linking agent is 0.01 to 0.5 g; Preferably, in step (2), based on 100 mg of the monomer, the amount of the initiator is 1 to 15 mg.

5. The preparation method according to any one of claims 1 to 4, It is characterized in that The functional molecules in step (3) include drugs and / or active factors; Preferably, the drug includes any one of antibacterial agents, antibiotic drugs, anti-inflammatory drugs, and immunomodulatory drugs, or a combination of at least two thereof; Preferably, the drug comprises any one of curcumin, idarubicin, cisplatin, ligustrazine, icariin, epirubicin, pharmacine, and crystal violet, or a combination of at least two thereof; Preferably, the active factors include any one of basic fibroblast growth factor, matrix metalloproteinase 9, brain-derived neurotrophic factor, and neurotrophin III, or a combination of at least two thereof; Preferably, the solvent in step (3) comprises any one of water, saline, and dimethyl sulfoxide, or a combination of at least two thereof; Preferably, in step (3), based on 100 mL of solvent, the amount of the functional molecule is 1 to 5 g.

6. The preparation method according to any one of claims 1 to 5, It is characterized in that The operating parameters of the injection pumps in step (3) are as follows: the injection speed of the first injection pump is 1 to 20 mL / h, and the injection speed of the second injection pump is 0.01 to 5 mL / h; Preferably, the coaxial glue dispensing needle in step (3) comprises any one of coaxial glue dispensing two needles, coaxial glue dispensing three needles, coaxial glue dispensing four needles, or a combination of at least two of them, preferably coaxial glue dispensing two needles; Preferably, the two coaxial dispensing needles include inner and outer needles with flush outlets, inner needle protruding 0.1 to 0.5 mm, and inner needle retracting 0.1 to 0.3 mm, preferably, the inner needle protruding 0.2 mm; Preferably, the inner needle specification of the two coaxial dispensing needles is 21-32G, and the outer needle specification is 10-25G.

7. The preparation method according to any one of claims 1 to 6, It is characterized in that The reaction medium in step (4) is a mixture of dimethyl silicone oil and Span 80, and the volume ratio of dimethyl silicone oil to Span 80 is 100:0.1-5; Preferably, the distance below the coaxial dispensing needle in step (4) is 1 to 10 mm; Preferably, the dripping speed of the droplets in step (4) is 10 to 60 drops / minute; Preferably, the stirring speed in step (4) is 50 to 200 r / min; Preferably, the stirring time in step (4) is 5 to 20 minutes; Preferably, the curing method in step (4) is photoinitiation or thermal initiation, preferably ultraviolet light initiation; Preferably, the wavelength of the ultraviolet light is 330 to 450 nm, and the ultraviolet light irradiation time is 1 to 5 min; Preferably, the post-treatment in step (4) comprises centrifuging to remove the upper layer of the reaction medium, washing with an organic solvent to remove the remaining reaction medium, and finally washing with pure water and freeze-drying; Preferably, the centrifugal speed is 500-1000 r / min, and the centrifugal time is 3-8 min; Preferably, the organic solvent is selected from any one of anhydrous ether, anhydrous ethanol, toluene, or a combination of at least two thereof, preferably anhydrous ethanol.

8. A functional microsphere, It is characterized in that The functional microspheres are prepared by the preparation method according to any one of claims 1 to 7.

9. The functional microsphere according to claim 8, It is characterized in that The functional microspheres are of intelligent response type, including temperature response type, and preferably have thermal stimulation self-contraction behavior in the temperature response type; Preferably, the shrinkage deformation of the functional microspheres is 1 to 50%; Preferably, the functional microspheres have self-adhesive properties, and their lap-shear strength is 1 to 1000 KPa; Preferably, the functional microspheres have a mechanical strength of 0.1 to 10 MPa, a deformation range of 10 to 200%, and an elastic modulus of 0.01 to 1 MPa; Preferably, the surface structure of the functional microspheres is a smooth spherical structure, which is not easy to clog the catheter; Preferably, the degradation period of the functional microspheres is 7 to 365 days, preferably 1 to 6 months; Preferably, the functional microspheres are hydrogel structures with a swelling rate of 50 to 500% w / w; Preferably, the diameter of the functional microspheres is 1 μm to 50 mm, preferably 100 to 1000 μm.

10. Use of the functional microspheres according to any one of claims 1 to 7 in embolic therapy drugs.